Telmisartan (Micardis) and Amlodipine (Norvasc) - Factorial Design Study for the Treatment of Hypertension

Phase 3

Completed

Conditions: Hypertension

Interventions: Drug: Amlodipine 2.5 mg
Drug: Amlodipine 5 mg
Drug: Telmisartan 20 mg
Drug: Telmisartan 40 mg
Drug: Placebo
Drug: Telmisartan 80 mg
Drug: Amlodipine 10 mg

Registration Number: NCT00281580

Lead Sponsor: Boehringer Ingelheim

Brief Summary: To demonstrate that Micardis and Norvasc when used together are more effective at lowering blood pre ssure.

Detailed Description: Not available

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 1461

Inclusion Criteria

Male and female patients >=18 years of age with Stage I or II hypertension defined as: a mean seated cuff diastolic blood pressure >=95 and <=119 mmHg Main

Exclusion criteria:

Exclusion Criteria

Patient is pregnant; breast-feeding; unwilling to use birth control during the study; has secondary hypertension; severe renal dysfunction; hepatic insufficiency; stroke within the last six months; myocardial infarction, cardiac surgery, percutaneous transluminal coronary angioplasty, unstable angina or coronary artery bypass graft within the past three months; unstable or uncontrolled diabetes for the past three months defined as a glucosylates hemoglobin (HbA1c) greater than ten percent ; history of angioedema or hypersensitivity related to either study drug.
Systolic Blood Pressure (SBP) is greater than or equal to 180 millimeters of mercury (mmHg), Diastolic Blood Pressure (DBP) is greater than or equal to 110 mmHg.

Study & Design

Study Type: INTERVENTIONAL

Study Design: FACTORIAL

Arm && Interventions

Group	Intervention	Description
Telmisartan 80 / Amlodipine 2.5	Telmisartan 80 mg	Telmisartan 80 / Amlodipine 2.5 for eight weeks
Telmisartan 40 / Amlodipine 2.5	Amlodipine 2.5 mg	Telmisartan 40 / Amlodipine 2.5 for eight weeks
Telmisartan 80 / Amlodipine 10	Telmisartan 80 mg	Telmisartan 40 / Amlodipine 5 for two weeks and forced titrated to amlodipine 10 mg for six weeks
Telmisartan 80 / Amlodipine 5	Telmisartan 80 mg	Telmisartan 80 / Amlodipine 5 mg for eight weeks
Telmisartan 80 / Amlodipine 10	Amlodipine 5 mg	Telmisartan 40 / Amlodipine 5 for two weeks and forced titrated to amlodipine 10 mg for six weeks
Telmisartan 80 mg	Telmisartan 80 mg	Telmisartan 80 mg once daily for eight weeks
Telmisartan 20 / Amlodipine 2.5	Telmisartan 20 mg	Telmisartan 20/ Amlodipine 2.5 mg once daily for eight weeks
Telmisartan 80 / Amlodipine 2.5	Amlodipine 2.5 mg	Telmisartan 80 / Amlodipine 2.5 for eight weeks
Amlodipine 2.5 mg	Amlodipine 2.5 mg	Amlodipine 2.5 mg once daily for eight weeks
Telmisartan 40 / Amlodipine 10	Telmisartan 40 mg	Telmisartan 40 / Amlodipine 5 for two weeks and forced titrated to amlodipine 10 mg for six weeks
Placebo	Placebo	Placebo once daily for eight weeks
Telmisartan 20 / Amlodipine 2.5	Amlodipine 2.5 mg	Telmisartan 20/ Amlodipine 2.5 mg once daily for eight weeks
Telmisartan 40 mg	Telmisartan 40 mg	Telmisartan 40 mg once daily for eight weeks
Telmisartan 20 / Amlodipine 10	Telmisartan 20 mg	Telmisartan 20 / Amlodipine 5 for two weeks and forced titrated to amlodipine 10 mg for six weeks
Telmisartan 20 mg	Telmisartan 20 mg	Telmisartan 20 mg once daily for eight weeks
Amlodipine 10 mg	Amlodipine 10 mg	Amlodipine 5 mg for two weeks and forced titrated to amlodipine 10 mg for six weeks once daily
Telmisartan 20 / Amlodipine 5	Telmisartan 20 mg	Telmisartan 20 / Amlodipine 5 mg once daily for eight weeks
Telmisartan 40 / Amlodipine 2.5	Telmisartan 40 mg	Telmisartan 40 / Amlodipine 2.5 for eight weeks
Telmisartan 40 / Amlodipine 5	Telmisartan 40 mg	Telmisartan 40 / Amlodipine 5 for eight weeks
Amlodipine 5 mg	Amlodipine 5 mg	Amlodipine 5 mg once daily for eight weeks
Amlodipine 10 mg	Amlodipine 5 mg	Amlodipine 5 mg for two weeks and forced titrated to amlodipine 10 mg for six weeks once daily
Telmisartan 20 / Amlodipine 5	Amlodipine 5 mg	Telmisartan 20 / Amlodipine 5 mg once daily for eight weeks
Telmisartan 20 / Amlodipine 10	Amlodipine 5 mg	Telmisartan 20 / Amlodipine 5 for two weeks and forced titrated to amlodipine 10 mg for six weeks
Telmisartan 20 / Amlodipine 10	Amlodipine 10 mg	Telmisartan 20 / Amlodipine 5 for two weeks and forced titrated to amlodipine 10 mg for six weeks
Telmisartan 40 / Amlodipine 5	Amlodipine 5 mg	Telmisartan 40 / Amlodipine 5 for eight weeks
Telmisartan 40 / Amlodipine 10	Amlodipine 10 mg	Telmisartan 40 / Amlodipine 5 for two weeks and forced titrated to amlodipine 10 mg for six weeks
Telmisartan 40 / Amlodipine 10	Amlodipine 5 mg	Telmisartan 40 / Amlodipine 5 for two weeks and forced titrated to amlodipine 10 mg for six weeks
Telmisartan 80 / Amlodipine 5	Amlodipine 5 mg	Telmisartan 80 / Amlodipine 5 mg for eight weeks
Telmisartan 80 / Amlodipine 10	Amlodipine 10 mg	Telmisartan 40 / Amlodipine 5 for two weeks and forced titrated to amlodipine 10 mg for six weeks

Primary Outcome Measures

Name	Time	Method
Change From Baseline at 8 Weeks in Seated Trough Cuff Mean DBP (Adjusted Telmisartan Effects)	Baseline to end-of-study (up to 8 weeks) visit (LOCF)	Results stem from an ANCOVA including the main effects of treatment with telmisartan, treatment with amlodipine, and country/region with baseline DBP included as a covariate.
Change From Baseline at 8 Weeks in Seated Trough Cuff Mean DBP (Observed Amlodipine Effects)	Baseline to end-of-study (up to 8 weeks) visit (LOCF)	Observed results
Change From Baseline at 8 Weeks in Seated Trough Cuff Mean DBP (Observed Treatment Effects)	End-of-study visit (LOCF)	Observed results
Change From Baseline at 8 Weeks in Seated Trough Cuff Mean DBP (Adjusted Treatment Effects)	Baseline to end-of-study (up to 8 weeks) visit (LOCF)	Results stem from an ANCOVA including the main effects of treatment with telmisartan, treatment with amlodipine, and country/region with baseline DBP included as a covariate.
Change From Baseline at 8 Weeks in Seated Trough Cuff Mean DBP (Adjusted Treatment Effects, Excluding Pl)	Baseline to end-of-study (up to 8 weeks) visit (LOCF)	Results stem from an ANCOVA including the main effects of treatment with telmisartan, treatment with amlodipine, and country/region with baseline DBP included as a covariate.
Change From Baseline at 8 Weeks in Seated Trough Cuff Mean Diastolic Blood Pressure (DBP) (Observed Telmisartan Effect)	Baseline to end-of-study (up to 8 weeks) visit (Last Observation Carried Forward (LOCF))	Observed results
Change From Baseline at 8 Weeks in Seated Trough Cuff Mean DBP (Adjusted Amlodipine Effects)	Baseline to end-of-study (up to 8 weeks) visit (LOCF)	Results stem from an ANCOVA including the main effects of treatment with telmisartan, treatment with amlodipine, and country/region with baseline DBP included as a covariate.
Change From Baseline in Seated Trough Cuff Mean DBP (Observed Telmisartan Effect)	Baseline to end-of-study (up to 8 weeks) visit (LOCF)	Observed results
Change From Baseline in Seated Trough Cuff Mean DBP (Observed Amlodipine Effects)	Up to 8 weeks (LOCF)	Observed results
Change From Baseline in Seated Trough Cuff Mean DBP (Adjusted Amlodipine Effects)	Up to 8 weeks (LOCF)	Results stem from an ANCOVA including the main effects of treatment with telmisartan, treatment with amlodipine, and country/region with baseline DBP included as a covariate.
Change From Baseline in Seated Trough Cuff Mean DBP (Adjusted Treatment Effects)	Up to 8 weeks (LOCF)	Results stem from an ANCOVA including the main effects of treatment with telmisartan, treatment with amlodipine, and country/region with baseline DBP included as a covariate.
Change From Baseline in Seated Trough Cuff Mean DBP (Adjusted Telmisartan Effects)	Baseline to end-of-study (up to 8 weeks) visit (LOCF)	Results stem from an ANCOVA including the main effects of treatment with telmisartan, treatment with amlodipine, and country/region with baseline DBP included as a covariate.
Change From Baseline in Seated Trough Cuff Mean DBP (Observed Treatment Effects)	Up to 8 weeks (LOCF)	Observed results
Change From Baseline in Seated Trough Cuff Mean DBP (Adjusted Treatment Effects, Excluding Pl)	Up to 8 weeks (LOCF)	Results stem from an ANCOVA including the main effects of treatment with telmisartan, treatment with amlodipine, and country/region with baseline DBP included as a covariate.

Secondary Outcome Measures

Name	Time	Method
DBP Response	Up to 8 weeks (LOCF)	DBP response is defined as DBP \< 90 mmHg or a reduction of DBP of \>= 10 mmHg - key combination therapies
Change From Baseline in ABPM Hourly Mean (Relative to Dosing) DBP	Up to 8 weeks (LOCF)	Observed results for mod-sev patients - key combination therapies
Change From Baseline at 8 Weeks in Seated Trough Cuff Mean Systolic Blood Pressure (SBP)	Baseline to end-of-study (up to 8 weeks) visit (LOCF)	Results stem from an ANCOVA including the main effects of treatment with telmisartan, treatment with amlodipine, and country/region with baseline SBP included as a covariate.
Change From Baseline at 8 Weeks in Standing Trough Cuff Mean DBP	Baseline to end-of-study (up to 8 weeks) visit (LOCF)	Results stem from an ANCOVA including the main effects of treatment with telmisartan, treatment with amlodipine, and country/region with baseline DBP included as a covariate.
Change From Baseline at 8 Weeks in Standing Trough Cuff Mean SBP	Baseline to end-of-study (up to 8 weeks) visit (LOCF)	Results stem from an ANCOVA including the main effects of treatment with telmisartan, treatment with amlodipine, and country/region with baseline SBP included as a covariate.
DBP Control	Up to 8 weeks (LOCF)	DBP control is defined as DBP \< 90 mmHg - key combination therapies
SBP Response	Up to 8 weeks (LOCF)	SBP Response is defined as SBP \< 140 mmHg or a reduction of SBP of \>= 10 mmHg - key combination therapies
BP Normality	Up to 8 weeks (LOCF)	No: Mean seated SBP \>=140 and/or mean seated DBP \>=90 mmHg at trough High normal: mean seated SBP \>=130 and \<140 mmHg and mean seated DBP \>=85 and \<90 mmHg at trough Normal: mean seated SBP \>=120 and \<130 mmHg and mean seated DBP \>=80 and \<85 mmHg at trough Optimal: mean seated SBP \< 120 mmHg and mean seated DBP \<80 mmHg at trough - key combination therapies
Change From Baseline in ABPM Hourly Mean (Relative to Dosing) SBP	End-of-study (up to 8 weeks) visit (LOCF)	Observed results - key combination therapies
Change From Baseline in ABPM 24-hour Mean SBP	Up to 8 weeks (LOCF)	Observed results for mod-sev patients - key combination therapies
Change From Baseline in ABPM 24-hour Mean DBP	Up to 8 weeks (LOCF)	Observed results for mod-sev patients - key combination therapies
Change From Baseline in Seated Trough Pulse Rate	Up to 8 weeks (LOCF)	Observed results for mod-sev patients - key combination therapies
Orthostatic Change in Trough Cuff Mean DBP	Week 8	Calculated as seated minus standing for mod-sev patients - key combination therapies
Orthostatic Change in Trough Cuff Mean SBP	Week 8	Calculated as seated minus standing for mod-sev patients - key combination therapies
Change From Baseline in Seated Trough Cuff Mean SBP	Up to 8 weeks (LOCF)	Results stem from an ANCOVA including the main effects of treatment with telmisartan, treatment with amlodipine, and country/region with baseline SBP included as a covariate.
Change From Baseline in Standing Trough Cuff Mean DBP	Up to 8 weeks (LOCF)	Results stem from an ANCOVA including the main effects of treatment with telmisartan, treatment with amlodipine, and country/region with baseline DBP included as a covariate.
Clinical Relevant Abnormalities for Laboratory Parameters and Electrocardiogram (ECG)	8 weeks	Clinical relevant abnormalities for laboratory parameters and Electrocardiogram (ECG). New abnormal findings or worsening of baseline conditions were reported as Adverse Events related to treatment (cardiac disorders and investigations).
Change From Baseline in Standing Trough Cuff Mean SBP	Up to 8 weeks (LOCF)	Results stem from an ANCOVA including the main effects of treatment with telmisartan, treatment with amlodipine, and country/region with baseline SBP included as a covariate.

Trial Locations

Locations (136): 1235.1.203
🇲🇽
Col. Magdalena de las Salinas, Mexico
1235.1.208 "Ignacio Chávez"
🇲🇽
mexico DF, Mexico
1235.1.211 Obesidad Y Prevencion de Enfermedades
🇲🇽
Mexico, D.F., Mexico
1235.1.212 en Factores de riesgo cardiovascular
🇲🇽
Mexico, Mexico
1235.1.205 Fraccionamiento Industrias
🇲🇽
San Luis Potosi, Mexico
1235.1.207
🇲🇽
Zapopan, Jalisco, Mexico
1235.1.395 Boehringer Ingelheim Investigational Site
🇺🇸
Tustin, California, United States
1235.1.398 Boehringer Ingelheim Investigational Site
🇺🇸
Melbourne, Florida, United States
1235.1.366 Boehringer Ingelheim Investigational Site
🇺🇸
East Syracuse, New York, United States
1235.1.447 Boehringer Ingelheim Investigational Site
🇺🇸
Fredericksburg, Virginia, United States
1235.1.465 Boehringer Ingelheim Investigational Site
🇺🇸
Los Angeles, California, United States
1235.1.001 Boehringer Ingelheim Investigational Site
🇦🇷
BsAs, Argentina
1235.1.453 Boehringer Ingelheim Investigational Site
🇺🇸
Milford, Connecticut, United States
1235.1.374 Boehringer Ingelheim Investigational Site
🇺🇸
Columbus, Ohio, United States
1235.1.446 Boehringer Ingelheim Investigational Site
🇺🇸
Columbus, Ohio, United States
1235.1.415 Boehringer Ingelheim Investigational Site
🇺🇸
Indianapolis, Indiana, United States
1235.1.406 Boehringer Ingelheim Investigational Site
🇺🇸
San Diego, California, United States
1235.1.435 Boehringer Ingelheim Investigational Site
🇺🇸
Arkansas City, Kansas, United States
1235.1.379 Boehringer Ingelheim Investigational Site
🇺🇸
Lenexa, Kansas, United States
1235.1.389 Boehringer Ingelheim Investigational Site
🇺🇸
Huntsville, Alabama, United States
1235.1.368 Boehringer Ingelheim Investigational Site
🇺🇸
Huntsville, Alabama, United States
1235.1.457 Boehringer Ingelheim Investigational Site
🇺🇸
Fairhope, Alabama, United States
1235.1.420 Boehringer Ingelheim Investigational Site
🇺🇸
Tempe, Arizona, United States
1235.1.444 Boehringer Ingelheim Investigational Site
🇺🇸
Encinitas, California, United States
1235.1.357 Boehringer Ingelheim Investigational Site
🇺🇸
Long Beach, California, United States
1235.1.445 Boehringer Ingelheim Investigational Site
🇺🇸
Encino, California, United States
1235.1.352 Boehringer Ingelheim Investigational Site
🇺🇸
Pembroke Pines, Florida, United States
1235.1.351 Boehringer Ingelheim Investigational Site
🇺🇸
Melbourne, Florida, United States
1235.1.369 Boehringer Ingelheim Investigational Site
🇺🇸
Pembroke Pines, Florida, United States
1235.1.356 Boehringer Ingelheim Investigational Site
🇺🇸
Wichita, Kansas, United States
1235.1.399 Boehringer Ingelheim Investigational Site
🇺🇸
Carrollton, Texas, United States
1235.1.402 Boehringer Ingelheim Investigational Site
🇺🇸
Lake Jackson, Texas, United States
1235.1.302 Boehringer Ingelheim Investigational Site
🇿🇦
Boksburg, South Africa
1235.1.101 Clínica Médica
🇧🇷
Rio de Janeiro, Brazil
1235.1.002 Boehringer Ingelheim Investigational Site
🇦🇷
Carlos Paz, Argentina
1235.1.102 Liga de Hipertensão Arterial
🇧🇷
Goiania, Brazil
1235.1.004 Boehringer Ingelheim Investigational Site
🇦🇷
Buenos Aires, Argentina
1235.1.202
🇲🇽
Guadalajara, Jalisco, Mexico
1235.1.115 Universidade Federal do Pará
🇧🇷
Belém, Brazil
1235.1.210 Consultorio Privado
🇲🇽
Durango, Durango, Mexico
1235.1.103 Unidade de Hipertensão - ICHC -
🇧🇷
São Paulo, Brazil
1235.1.209 Boehringer Ingelheim Investigational Site
🇲🇽
Guadalajara, Jalisco, Mexico
1235.1.204
🇲🇽
Lomas de Guevara, Guadalajara, Mexico
1235.1.304 Boehringer Ingelheim Investigational Site
🇿🇦
Durban, South Africa
1235.1.307 Boehringer Ingelheim Investigational Site
🇿🇦
Krugersdorp, South Africa
1235.1.301 Boehringer Ingelheim Investigational Site
🇿🇦
Pretoria, South Africa
1235.1.314 Boehringer Ingelheim Investigational Site
🇿🇦
Benoni, South Africa
1235.1.309 Boehringer Ingelheim Investigational Site
🇿🇦
Cape Town, South Africa
1235.1.312 Boehringer Ingelheim Investigational Site
🇿🇦
Johannesburg, South Africa
1235.1.306 Boehringer Ingelheim Investigational Site
🇿🇦
Cape Town, South Africa
1235.1.311 Boehringer Ingelheim Investigational Site
🇿🇦
Cape Town, South Africa
1235.1.305 Boehringer Ingelheim Investigational Site
🇿🇦
Lenasia, South Africa
1235.1.303 Boehringer Ingelheim Investigational Site
🇿🇦
Lenasia, South Africa
1235.1.109 Centro de Pesquisas do Hospital do Rim e Hipertensão
🇧🇷
São Paulo, Brazil
1235.1.313 Boehringer Ingelheim Investigational Site
🇿🇦
Johannesburg, South Africa
1235.1.409 Boehringer Ingelheim Investigational Site
🇺🇸
Sacramento, California, United States
1235.1.407 Boehringer Ingelheim Investigational Site
🇺🇸
Tampa, Florida, United States
1235.1.423 Boehringer Ingelheim Investigational Site
🇺🇸
Louisville, Kentucky, United States
1235.1.384 Boehringer Ingelheim Investigational Site
🇺🇸
Winston-Salem, North Carolina, United States
1235.1.361 Boehringer Ingelheim Investigational Site
🇺🇸
Oklahoma City, Oklahoma, United States
1235.1.358 Boehringer Ingelheim Investigational Site
🇺🇸
Salt Lake City, Utah, United States
1235.1.458 Boehringer Ingelheim Investigational Site
🇺🇸
Winston-Salem, North Carolina, United States
1235.1.359 Boehringer Ingelheim Investigational Site
🇺🇸
Oklahoma City, Oklahoma, United States
1235.1.440 Boehringer Ingelheim Investigational Site
🇺🇸
Portland, Oregon, United States
1235.1.436 Boehringer Ingelheim Investigational Site
🇺🇸
Oklahoma City, Oklahoma, United States
1235.1.448 Boehringer Ingelheim Investigational Site
🇺🇸
Oklahoma City, Oklahoma, United States
1235.1.439 Boehringer Ingelheim Investigational Site
🇺🇸
Portland, Oregon, United States
1235.1.464 Boehringer Ingelheim Investigational Site
🇺🇸
Salt Lake City, Utah, United States
1235.1.454 Boehringer Ingelheim Investigational Site
🇺🇸
Henderson, Nevada, United States
1235.1.390 Boehringer Ingelheim Investigational Site
🇺🇸
Hialeah, Florida, United States
1235.1.380 Boehringer Ingelheim Investigational Site
🇺🇸
Tucker, Georgia, United States
1235.1.411 Boehringer Ingelheim Investigational Site
🇺🇸
Huntsville, Alabama, United States
1235.1.391 Boehringer Ingelheim Investigational Site
🇺🇸
Cudahy, California, United States
1235.1.441 Boehringer Ingelheim Investigational Site
🇺🇸
Riverside, California, United States
1235.1.414 Boehringer Ingelheim Investigational Site
🇺🇸
Santa Ana, California, United States
1235.1.383 Boehringer Ingelheim Investigational Site
🇺🇸
Spring Valley, California, United States
1235.1.354 Boehringer Ingelheim Investigational Site
🇺🇸
Cooper City, Florida, United States
1235.1.451 Boehringer Ingelheim Investigational Site
🇺🇸
Deland, Florida, United States
1235.1.372 Boehringer Ingelheim Investigational Site
🇺🇸
Fort Lauderdale, Florida, United States
1235.1.396 Boehringer Ingelheim Investigational Site
🇺🇸
Fort Lauderdale, Florida, United States
1235.1.430 Boehringer Ingelheim Investigational Site
🇺🇸
Kissimmee, Florida, United States
1235.1.405 Boehringer Ingelheim Investigational Site
🇺🇸
Mirimar, Florida, United States
1235.1.397 Boehringer Ingelheim Investigational Site
🇺🇸
Pembroke Pines, Florida, United States
1235.1.355 Boehringer Ingelheim Investigational Site
🇺🇸
Rockledge, Florida, United States
1235.1.449 Boehringer Ingelheim Investigational Site
🇺🇸
Pensacola, Florida, United States
1235.1.438 Boehringer Ingelheim Investigational Site
🇺🇸
Gurnee, Illinois, United States
1235.1.373 Boehringer Ingelheim Investigational Site
🇺🇸
Evansville, Indiana, United States
1235.1.412 Boehringer Ingelheim Investigational Site
🇺🇸
South Bend, Indiana, United States
1235.1.375 Boehringer Ingelheim Investigational Site
🇺🇸
Evansville, Indiana, United States
1235.1.421 Boehringer Ingelheim Investigational Site
🇺🇸
Newtown, Kansas, United States
1235.1.424 Boehringer Ingelheim Investigational Site
🇺🇸
Bay City, Michigan, United States
1235.1.387 Boehringer Ingelheim Investigational Site
🇺🇸
North Dartmouth, Massachusetts, United States
1235.1.385 Boehringer Ingelheim Investigational Site
🇺🇸
Florissant, Missouri, United States
1235.1.452 Boehringer Ingelheim Investigational Site
🇺🇸
Florissant, Missouri, United States
1235.1.434 Boehringer Ingelheim Investigational Site
🇺🇸
Stratford, New Jersey, United States
1235.1.426 Boehringer Ingelheim Investigational Site
🇺🇸
Cherry Hill, New Jersey, United States
1235.1.427 Boehringer Ingelheim Investigational Site
🇺🇸
Rochester, New York, United States
1235.1.381 Boehringer Ingelheim Investigational Site
🇺🇸
Williamsville, New York, United States
1235.1.410 Boehringer Ingelheim Investigational Site
🇺🇸
Burlington, North Carolina, United States
1235.1.376 Boehringer Ingelheim Investigational Site
🇺🇸
Raleigh, North Carolina, United States
1235.1.400 Boehringer Ingelheim Investigational Site
🇺🇸
Charlotte, North Carolina, United States
1235.1.403 Boehringer Ingelheim Investigational Site
🇺🇸
Lenior, North Carolina, United States
1235.1.422 Boehringer Ingelheim Investigational Site
🇺🇸
Greenboro, North Carolina, United States
1235.1.392 Boehringer Ingelheim Investigational Site
🇺🇸
Raleigh, North Carolina, United States
1235.1.413 Boehringer Ingelheim Investigational Site
🇺🇸
Marion, Ohio, United States
1235.1.386 Boehringer Ingelheim Investigational Site
🇺🇸
Tulsa, Oklahoma, United States
1235.1.404 Boehringer Ingelheim Investigational Site
🇺🇸
Lansdale, Pennsylvania, United States
1235.1.408 Boehringer Ingelheim Investigational Site
🇺🇸
Erie, Pennsylvania, United States
1235.1.428 Boehringer Ingelheim Investigational Site
🇺🇸
Penndel, Pennsylvania, United States
1235.1.370 Boehringer Ingelheim Investigational Site
🇺🇸
East Providence, Rhode Island, United States
1235.1.459 Boehringer Ingelheim Investigational Site
🇺🇸
Jackson, Tennessee, United States
1235.1.417 Boehringer Ingelheim Investigational Site
🇺🇸
Cordova, Tennessee, United States
1235.1.460 Boehringer Ingelheim Investigational Site
🇺🇸
Dallas, Texas, United States
1235.1.443 Boehringer Ingelheim Investigational Site
🇺🇸
Georgetown, Texas, United States
1235.1.416 Boehringer Ingelheim Investigational Site
🇺🇸
Killeen, Texas, United States
1235.1.456 Boehringer Ingelheim Investigational Site
🇺🇸
Odessa, Texas, United States
1235.1.418 Boehringer Ingelheim Investigational Site
🇺🇸
Plano, Texas, United States
1235.1.432 Boehringer Ingelheim Investigational Site
🇺🇸
McKinney, Texas, United States
1235.1.455 Boehringer Ingelheim Investigational Site
🇺🇸
Waco, Texas, United States
1235.1.437 Boehringer Ingelheim Investigational Site
🇺🇸
Burke, Virginia, United States
1235.1.371 Boehringer Ingelheim Investigational Site
🇺🇸
Tacoma, Washington, United States
1235.1.005 Boehringer Ingelheim Investigational Site
🇦🇷
Buenos Aires, Argentina
1235.1.006 Boehringer Ingelheim Investigational Site
🇦🇷
Buenos Aires, Argentina
1235.1.310 Boehringer Ingelheim Investigational Site
🇿🇦
Cape Town, South Africa
1235.1.308 Boehringer Ingelheim Investigational Site
🇿🇦
Pretoria, South Africa
1235.1.394 Boehringer Ingelheim Investigational Site
🇺🇸
Newark, Delaware, United States
1235.1.433 Boehringer Ingelheim Investigational Site
🇺🇸
Beaufort, South Carolina, United States
1235.1.003 Boehringer Ingelheim Investigational Site
🇦🇷
Cordoba, Argentina
1235.1.429 Boehringer Ingelheim Investigational Site
🇺🇸
Chandler, Arizona, United States
1235.1.365 Boehringer Ingelheim Investigational Site
🇺🇸
Kansas City, Missouri, United States
1235.1.431 Boehringer Ingelheim Investigational Site
🇺🇸
Kansas City, Missouri, United States
1235.1.442 Boehringer Ingelheim Investigational Site
🇺🇸
Austin, Texas, United States
1235.1.462 Boehringer Ingelheim Investigational Site
🇺🇸
Union, South Carolina, United States
1235.1.377 Boehringer Ingelheim Investigational Site
🇺🇸
Northport, New York, United States
1235.1.363 Boehringer Ingelheim Investigational Site
🇺🇸
New Tazewell, Tennessee, United States
1235.1.382 Boehringer Ingelheim Investigational Site
🇺🇸
Selmer, Tennessee, United States